Thais Aragão Horoiwa

Ms. Thais Aragão Horoiwa

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
THThais Aragão Horoiwa
Thais Aragão Horoiwa
MCMauro Cortez
Mauro Cortez
ISIsmael Pretto Sauter
Ismael Pretto Sauter
AMAmanda Migotto
Amanda Migotto
CBCarla Letícia Bandeira
Carla Letícia Bandeira
AOAdriano M. de Oliveira
Adriano M. de Oliveira

1 January 2019 in Materials Research
Verified
Journal Article
Open access
PDF file
THThais Aragão Horoiwa
Thais Aragão Horoiwa
AOAdriano Marim de Oliveira
Adriano Marim de Oliveira
AMAmanda Migotto
Amanda Migotto
NCNatalia Neto Pereira Cerize
Natalia Neto Pereira Cerize
Several studies have demonstrated that sugar-based nanocarriers are recommended to develop drug delivery systems since they are biocompatible and biodegradable and might improve the therapeutic index of currently used drugs by reducing their toxicity and enhancing their bioavailability. Therewith, this work studied the processing conditions to formation of a sugar-based nanocarrier denominated polymeric colloidal nanocarriers (PCN). It reports the impact of emulsifiers types and concentration, salt concentration and copolymers addition on physical stability and particle size distribution of a maltodextin-based PCN. In order to define the most stable formulation to produce the maltodextrin nanocarriers, 13 PCN formulations were evaluated in respect to kinetic stability, particle size distribution and morphology. The results demonstrated that to have a stable sugar-based PCN in silicone for at least 3 days, it is necessary to work with Poloxamer 188 as a copolymer, SF 1540 surfactant in a concentration proportional to the solid content and a salt concentration of 0.4 %.

1 January 2017 in Revista IPT: Tecnologia e Inovação
Verified
Journal Article
Closed access
PDF file
THThais Aragão Horoiwa
Thais Aragão Horoiwa
AOAdriano Marim Oliveira
Adriano Marim Oliveira
NCNatália Neto Pereira Cerize
Natália Neto Pereira Cerize
Development of polymeric colloidal nanocarrier based on maltodextrin

1 October 2014
Verified
Conference Paper
Closed access
JSJuliana N. Schianti
Juliana N. Schianti
Mario Ricardo Gongora RubioMario Ricardo Gongora Rubio
Mario Ricardo Gongora Rubio
THThais Aragão Horoiwa
Thais Aragão Horoiwa
NCNatália Neto Pereira Cerize
Natália Neto Pereira Cerize
AOA. M. Oliveira
A. M. Oliveira
In this work we present the first results related to production of water nanoemulsion in diesel oil using microfluidic reactors as tool. We tested two different microreactors, a vortex and 3D serpentine geometry, varying parameters such as total flow rate, surfactant concentration and ratio between phases. It was observed water droplets sizes from 100 to 700 nm, and the stability was dependent of surfactant concentration. Higher flow rates offer smaller droplets sizes obtained in vortex device. However, with 3D serpentine we observed nanoemulsion with better stability.

1 January 2017 in Revista IPT: Tecnologia e Inovação
Verified
Journal Article
Closed access
PDF file
THThais Aragão Horoiwa
Thais Aragão Horoiwa
AOAdriano Marim Oliveira
Adriano Marim Oliveira
NCNatália Neto Pereira Cerize
Natália Neto Pereira Cerize
Avaliação da contribuição de copolímero de bloco PEG/PPG na estabilidade coloidal de nanocarreadores

1 June 2026 in Clinical & Translational Immunology
Verified
Journal Article
Open access
BZBijun Zeng
Bijun Zeng
MTMeghna Talekar
Meghna Talekar
THThais Aragão Horoiwa
Thais Aragão Horoiwa
ACAmy Cameron
Amy Cameron
GZGuangzu Zhao
Guangzu Zhao
RTRanjeny Thomas
Ranjeny Thomas
Objectives: Cancer vaccines combine tumor antigen and adjuvant to drive an anti‐tumor immune response. Clec9A‐targeted nanoparticles directing CD4 and CD8 neo‐epitopes to cross‐presenting dendritic cells (DCs) stimulate adjuvant‐free therapeutically effective tumor‐specific immunity. However, personalised neo‐epitopes limit the scalability of Clec9A nanoparticles for clinical translation. Since Clec9A + DCs constitutively present relevant neoepitopes in tumors but are suppressed in tumor microenvironments, we developed Clec9A‐targeted STING or RIG‐I liposomes to enhance endogenous tumor immunity. Methods: Liposomes encapsulating RIG‐I or the STING agonist MSA‐1 and functionalised with Clec9A binding peptide WH were optimised for uptake by Clec9A + conventional and plasmacytoid DCs in vivo . Biodistribution after i.v. administration was determined with in vivo imaging and cellular uptake and activation with flow cytometry. Plasma was analysed for type 1 interferon (IFN) by ELISA and liver, spleen, tumor, blood, kidney, heart and tumor draining lymph node transcriptomes were analysed with Nanostring. Effects on tumor growth and survival, and tumor‐specific T cells were evaluated using the B16 melanoma model. Results: Clec9A‐targeting liposomes administered i.v. were distributed to spleen, liver and tumor and were taken up by cross‐presenting and plasmacytoid DCs. Type 1 IFN production and DC, B‐ and T‐cell activation were more effective with i.v. Clec9A‐STING than Clec9A‐RIG‐I liposomes. Intravenous Clec9A‐STING liposomes stimulated IFN‐dependent transcription in blood, lung, tumor, and draining lymph nodes. Intravenous Clec9A‐STING liposomes, or intra‐tumoral Clec9A‐RIG‐I liposomes significantly suppressed B16‐F10 melanoma growth and induced neo‐epitope and survivin‐specific CD4 + and CD8 + T‐cell responses. Conclusions: Clec9A‐STING liposomes are a scalable, translatable tumor‐targeted immunotherapy platform.